The weight loss drug market exploded in 2026 with new formulations, higher doses, and a blockbuster newcomer. CagriSema, Novo Nordisk's next-generation combination drug, is heading toward FDA approval — but does it actually beat the incumbents? We compared CagriSema, Ozempic, Wegovy, and Zepbound across efficacy, side effects, cost, and availability to help you understand which drug delivers the most weight loss and which one you can actually get.
- CagriSema achieves 22.7% weight loss in 68 weeks — but lost to Zepbound in a head-to-head trial
- Wegovy HD (7.2 mg), approved March 2026, delivers 20.7% weight loss — the strongest approved Wegovy injection yet
- Zepbound (tirzepatide) remains the weight loss leader at 22.5–25.5% reduction at max dose
- Oral Wegovy pill launched January 2026 at $149/month — first GLP-1 pill for weight loss
- CagriSema FDA decision expected late 2026; not yet available to patients
How These Drugs Work
All four medications target the GLP-1 receptor, which regulates appetite and blood sugar. But they do it differently — and that difference matters for results.
Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist. The difference is labeling: Ozempic is approved for type 2 diabetes, while Wegovy is approved specifically for weight management. Same molecule, different indications.
Zepbound (tirzepatide) is a dual GLP-1 and GIP receptor agonist made by Eli Lilly. By hitting two receptors instead of one, it generally produces stronger appetite suppression and greater weight loss than semaglutide alone.
CagriSema combines semaglutide with cagrilintide, a long-acting amylin analogue. Amylin is a hormone your pancreas releases alongside insulin that slows stomach emptying and signals fullness. The theory: two mechanisms working together should outperform semaglutide alone.
Weight Loss Results Compared
This is what everyone wants to know. Here's how they stack up based on clinical trial data:
| Drug | Avg. Weight Loss | Trial Duration | Key Trial |
|---|---|---|---|
| Zepbound (15 mg) | 22.5–25.5% | 72–84 weeks | SURMOUNT / REDEFINE 4 |
| CagriSema (2.4 mg) | 22.7% (68 wk) / 23.0% (84 wk) | 68–84 weeks | REDEFINE 1 & 4 |
| Wegovy HD (7.2 mg) | 20.7% | 72 weeks | STEP UP |
| Wegovy (2.4 mg) | 15–17% | 68 weeks | STEP 1–4 |
| Oral Wegovy (25 mg pill) | 13.6% | 64 weeks | OASIS 4 |
| Ozempic (2 mg) | 6–10% | 68 weeks | SUSTAIN trials |
That said, CagriSema still beat standard Wegovy and crushed Ozempic. In the REIMAGINE study, CagriSema delivered 14.2% weight loss versus 10.2% for semaglutide (Ozempic) in type 2 diabetes patients — a meaningful gap.
Side Effects: What to Expect
All GLP-1 drugs share a similar side effect profile. The gastrointestinal effects are the price of admission:
CagriSema Side Effects vs Zepbound Side Effects
- Nausea: ~55% of patients | Nausea: ~30–35% of patients
- Vomiting: moderate | Vomiting: moderate
- Diarrhea: common | Diarrhea: common
- Constipation: common | Constipation: common
- Discontinuation rate: 5.9–8.4% | Discontinuation rate: ~6–7% ::/versus
CagriSema's nausea rate is notably higher than Zepbound's — likely because you're combining two mechanisms that both slow gastric emptying. Most side effects are mild to moderate and fade with dose escalation over weeks.
Serious risks (rare, all drugs): pancreatitis, gallbladder problems, and thyroid concerns. None of these drugs are recommended for people with a history of medullary thyroid cancer or MEN2 syndrome.
Cost and Insurance in 2026
Pricing is where the rubber meets the road. You can have the most effective drug in the world, but it's useless if you can't afford it.
Availability: What You Can Actually Get Right Now
| Drug | Status (March 2026) | How to Get It |
|---|---|---|
| Ozempic | ✅ Available (injection + oral tablets Q2 2026) | Prescription for type 2 diabetes |
| Wegovy | ✅ Available (injection, oral pill, HD dose) | Prescription for weight management |
| Zepbound | ✅ Available | Prescription for weight management |
| CagriSema | ❌ Not approved | FDA decision expected late 2026 |
Wegovy had the biggest year so far: the oral pill launched in January 2026, and the high-dose 7.2 mg injection (Wegovy HD) was approved on March 19, 2026, with U.S. launch expected April 2026.
Who Should Consider Each Drug
The Bottom Line
If maximum weight loss is your priority: Zepbound wins. It's FDA-approved, available now, and consistently delivers the highest percentage of body weight reduction. The April 2026 Medicare price cap makes it more accessible than ever.
If you want an oral option: Oral Wegovy is a breakthrough for people who hate needles. At $149/month and 13.6% average weight loss, it's the most convenient entry point.
If you have type 2 diabetes: CagriSema showed the best combined weight loss and blood sugar results in diabetes patients — but it's not available yet. In the meantime, Wegovy HD or Mounjaro (Zepbound's diabetes-approved sibling) are your best bets.
Should you wait for CagriSema? Probably not. The REDEFINE 4 trial showed it doesn't beat Zepbound, and it won't be available until late 2026 at the earliest. If you're considering treatment now, Zepbound or Wegovy HD are the proven winners.
The weight loss drug race is far from over. Novo Nordisk is already planning a higher-dose CagriSema trial for H2 2026, and Eli Lilly has an oral tirzepatide in the pipeline. By 2027, the options — and the competition driving prices down — will only accelerate.
